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Background: In recent years, scaling up of antiretroviral therapy (ART) in resource-limited settings moved
impressively towards universal access. Along with these achievements, public health HIV programs are facing
a number of challenges including the support of patients on lifelong therapy and the prevention of temporary/
permanent loss of patients in care. Understanding reasons for treatment interruption (TI) can inform
strategies for improving drug adherence and retention in care.
Objective: To evaluate key characteristics of patients resuming ART after TI at the Lighthouse Clinic in
Lilongwe, Malawi, and to identify their reasons for interrupting ART.
Design: This study uses a mixed methods design to evaluate patients resuming ART after TI. We analysed an
assessment form for patients with TI using pre-defined categories and a comments field to identify frequently
stated reasons for TI. Additionally, we conducted 26 in-depth interviews to deepen our understanding of
common reasons for TI. In-depth interviews also included the patients’ knowledge about ART and presence
of social support systems. Qualitative data analysis was based on a thematic framework approach.
Results: A total of 347 patients (58.2% female, average age 35.1911.3 years) with TI were identified. Despite
the presence of social support and sufficient knowledge of possible consequences of TI, all patients
experienced situations that resulted in TI. Analysis of in-depth interviews led to new and distinct categories
for TI. The most common reason for TI was travel (54.5%, n80/147), which further differentiated into
work- or family-related travel. Patients also stated transport costs and health-care-provider-related reasons,
which included perceived/enacted discrimination by health care workers. Other drivers of TI were treatment
fatigue/forgetfulness, the patients’ health status, adverse drug effects, pregnancy/delivery, religious belief or
perceived/enacted stigma.
Conclusions: To adequately address patients’ needs on a lifelong therapy, adherence-counselling sessions
require provision of problem-solving strategies for common barriers to continuous care.
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I
nrecentyears,scalingupofpublichealthprogrammes
in resource-limited settings made considerable pro-
gress towards universal access to antiretroviral ther-
apy (ART) (1). By the end of 2011, an estimated 8 million
patients in low- and middle-income countries, equalling
54% of those in need, received ART (2). Expanding
coverage has been associated with a significant decrease
in morbidity and mortality related to the human immu-
nodeficiency virus (HIV) (37), and in reducing poten-
tially the risk of HIV transmission (8). However, the
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(page number not for citation purpose)effectiveness of ART is determined by continuous access
to treatment and retention in care (9). As demonstrated
by a systematic review of sub-Saharan countries, one in
fourpatientsdoesnotremainincare2yearsafterinitiation
of therapy (10).
The World Health Organization (WHO) defines adher-
encebroadly as ‘the extent towhich aperson’s behaviour 
taking medication, following a diet, and/or executing
lifestyle changes  corresponds with agreed recommenda-
tions from a health careprovider’ (11). Rosen et al. further
differentiatebetweenday-to-daydrug adherence, meaning
the mere daily intake of medication as prescribed, and
long-term retention in care (12). The latter puts adherence
into a broader context embracing lifelong adherence to
medication but also continuous attendance of programme
activities such as regular clinical visits, counselling and
patient education. In the context of increasing numbers
of patients in care, the continuous lifelong treatment at
the end of the HIV care pathway is of growing importance
(13). The patients’ engagement in care and the preven-
tion of permanent or temporary losses is crucial for
the effectiveness and success of ART, particularly for
future test-and-treat strategies for HIV prevention (14).
The probability of sexual HIV transmission is linked to
viral load levels (15), and effective ART has been shown
to reduce further transmission of HIV and consequently
the HIV incidence (16).
Long-term retention in care and day-to-day drug
adherence can prevent poor clinical outcomes for the
individual patient as well as the development and spread
of drug resistance mutations within a population (1720).
Even though developing countries achieve similar or even
higher adherence rates compared to those observed in
developed countries (2125), their ART regimen options
and technical ability to detect drug resistance are limited.
Under these circumstances, the preventive value of ad-
herence becomes even more pronounced as it may at least
partially compensate such deficits.
Non-adherence can either be expressed as percentage
of missed doses or as frequency and duration of complete
treatment interruption (TI) (26). TI has been associated
with a higher risk of drug resistance than intermittent
missed doses (20, 27). Consequently, it may be a more
useful predictor of clinical outcomes than pill count
alone (28).
A recent study from rural Malawi indicated that
after initiation of ART, retention in care shows a sharp
drop during the first months, primarily caused by high
mortality rates. In contrast, long-term retention is subject
to a more gradual decline mainly due to lost-to-follow-up
(LTFU) (29). Tweya et al. showed that patients LTFU
are a heterogeneous group and include patients who died,
received ART from another clinic or other source, or
actually stopped therapy (30). However, a considerable
proportion of patients stopping ART resume therapy
after some time, which is defined as TI (30, 31). This is
accompanied by a high risk of treatment failure caused
by evolving drug resistance (32).
Known reasons for TI include a range of economic,
structural, social and behavioural barriers to continuous
care (23). Approaches to increase the understanding of
factors associated with TI often rely on clinical data
about patient demographics and treatment regimen.
Although this information can be easily obtained and is
useful in defining risk groups, qualitative research can
provide a deeper understanding of patients’ individual
barriers to continuous care (33). In the past, treatment
costs were frequently reported to represent a major
obstacle, but this changed after ART became free of
charge in most sub-Saharan countries. Instead, more
recent research highlights transport costs as a common
impediment (34). In addition, factors related to the
patienthealth care provider relationship must not be
overlooked (22). Behavioural factors such as intrinsic
motivation and knowledge about HIV and ART are
interlinked with acceptance of medication and conse-
quently adherence to therapy (35). Consequently, research
efforts should aim at a more profound understanding
of reasons for TI to assure the integration of needs-based
adherence support into programme design. This study
aimed at understanding TI in greater depth by exploring
the following research questions:
1. What are the key characteristics of patients with
confirmed TI?
2. Which factors do patients have at their disposal to
support their day-to-day drug adherence and reten-
tion in care?
3. What main reasons do these patients report for
interrupting ART?
Methods
Study setting
This study was conducted at the Lighthouse Clinic in
Lilongwe, Malawi, one of the largest centres for ART in
the country. Since 2004, ART and regular clinical reviews
are provided free of charge and in accordance with the
national scale up programme and WHO’s Universal
Access strategy (19, 36, 37). Lighthouse routinely uses
a real-time electronic data system (EDS) for the collec-
tion of patient data and documentation of all visits,
prescriptions and dispensing. During clinic visits, pa-
tients’ adherence is assessed via pill count and patients
for whom the EDS calculates an adherence level B95%
are referred to one to one adherence-counselling sessions.
More details about the HIV epidemic in Malawi, the
national ART programme as well as the Lighthouse
as a centre of excellence for ART provision can be found
elsewhere (30, 3643).
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In 2006, the Back-to-Care Programme (B2C) was initiated
to improve patient retention in carevia earlyactive follow-
up. The programme uses the EDS to identify patients
who are overdue for their scheduled appointment ]21
days, defined as patients LTFU (30, 32). These patients
or their relatives/treatment supporters are contacted via
mobile phone and/or home visits in order to determine
their actual ART status. Using the standardized B2C
form, the team documents information about the patient’s
survival status, thelast clinic visit, thehistorysince thelast
visit as well as future intentions to continue ART and
return to care. Questions about the history since the last
visit include possible alternate ART sources, the mode
and frequency of pill intake and also possible reasons for
stopping ART. The B2C form mainly consists of a closed
format with either multiple options, date specifications
or dichotomous options (yes/no). Free-text commentary
fields allow for further specifications. The ART status
of the patient is recorded as either unsuccessful tracing
attempt, death of the patient, transfer to another ART
facility, uninterrupted therapy with alternate ART source,
never started ART or stop of all prescribed antiretroviral
drugs. All patients found alive who did not transfer to
another ART facility are encouraged to return to the
Lighthouse to resume therapy (30).
Study population
This study included patients ]15 years of age who
resumed ART after documented TI between January
2008 and November 2009. TI was given if the ART status
assessedbytheB2Cprogrammewas‘stopofallprescribed
antiretroviral drugs’ andif these patients returned toclinic
for ART resumption within the study period between
June and November 2009 (Fig. 1). Duration of TI was
calculated as the difference between estimated last pill day
and the day of return to the clinic.
Data collection
This study used a mixed methods analysis of quantita-
tive and qualitative data to evaluate patients resuming
ARTafter TI: their key characteristics, factors supporting
adherence and retention in care, as well as reasons for
stopping ART (Fig. 1). We quantified reasons for TI using
the B2C forms with pre-defined categories. In addition,
we performed in-depth interviews and evaluated free-text
comments of the B2C forms to 1) identify additional
reasons for TI and 2) gain a better understanding of the
individual circumstances leading to TI.
Patients’ characteristics
For all patients resuming therapy after TI (n347),
routinely collected patient data from the EDS (demo-
graphics, ART regimen, duration and frequency of TI)
was transferred into an MSAccess database.
B2C form
First of all, we compiled existing paper-based interview
forms from the B2C programme of patients with con-
firmed TI. The information captured in the B2C forms is
filled in by the B2C team based on answers obtained via
phone interviews or personal contact in the field before
these patients decide to return to care for resumption
of ART. In these forms, the B2C team summarizes the
patient’s reasons for stopping ART by selecting one or
more of eight pre-defined categories: 1) treatment fatigue/
forgetfulness, 2) adverse drug effects, 3) weakness/sickness,
4) religious reasons, 5) travel, 6) traditional medicine, 7)
transport costs or 8) other reason. The latter used an
open question field to allow for further specification or
to record not-listed reasons. The pre-defined categories
were developed on the basis of common reasons for TI
as found in the literature when the B2C programme was
initiated in 2006 (30).
We retrospectively analysed a subset of 147 forms of
all patients with TI who appeared in person at the clinic
within the enrolment period June to November 2009. This
enrolment strategy ensured that these patients could also
be approached for a prospective re-evaluation of their
reasons for TI (in-depth interview). These patients were
also consecutively enrolled in a linked study evaluating
virological outcomes in patients with TI (32). The paper-
based forms were double entered into a database for
further analysis.
In-depth interviews
Between June and November 2009, a subset of the
enrolled B2C patients (n26/147) were approached on
site for semi-structured in-depth interviews asking about
individual circumstances that led to TI. Reasons for TI
derived from the B2C form were used to select key topics
for the interview guide. We applied purposive sampling
based on the pre-defined B2C form categories to assure
selection of typical cases and to re-evaluate these cate-
gories. Patients were prospectively recruited until a point
of saturation was reached, meaning that no newaspects or
further themes emerged (44). Evaluating factors generally
known to support drug adherence and retention in care,
respondents’ perception of ART, knowledge about the
risk of treatment failure, the importance of adherence,
and the presence of support structures were also assessed.
In-depth interviews were conducted in the local language
Chichewa by one trained, experienced and indepen-
dent interviewer (not employed at Lighthouse). Interviews
were conducted in clinic rooms to ensure privacy and an
undisturbed environment, preceded in a conversational
style and were tape-recorded.
Data analysis
Quantitative data from the EDS and the B2C form was
analysed using STATA†/IC11 (StataCorp. LP, College
Station, TX). Continuous variables were described by
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n= 1,826 (12.9 %)
Patients aged  15 years on ART at the Lighthouse Clinic in 2008/2009
Patients traced by B2C team
n=1246
ART outcome
according to
B2C form
Patients NOT traced by B2C team
n= 580
Patients died (confirmed by relatives)
n=421
Patients stopped ART
n= 581 (4.1 %)
Patients returned to care
= patients with treatment interruption
n= 347 (2.6 %)
Mixed method data analysis
Consecutively enrolled patients
(Period: June - November 2009)
Patient characteristics (from EDS)
n= 347
B2C form (data entered)
n= 147
In-depth interviews
n= 26
Purposive sampling
based on the B2C form categories
Patients transferred to other facility,
other source of ART, never started ART
n= 244
> –
Patients LTFU (missed appointments    21 days) > –
Fig. 1. Study population. Eligibility criteriawere ]15 years, documented treatment interruption of ]21 days (between January
2008 and November 2009), resumption of ART. In total, patient characteristics of 347 patients were analysed, 147 B2C forms
were entered into an MSAccess database and 26 in-depth interviews were conducted for descriptive analysis and to gain a
further understanding of reasons for treatment interruption.
ART: Antiretroviral therapy; B2C: Back-to-Care; EDS: Electronic data system; LTFU: Lost-to-Follow up
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tributed data. Descriptive statistics also included ranges
and proportions, as appropriate. Significance of differ-
ence was tested using Students t test and x
2 as appro-
priate. Regression analysis with TI/duration of TI as
dependent variable adjusted for sex and/or age was per-
formed to evaluate key characteristics of patients with
TI. Level of significance was set at p50.05 and 95%
confidence interval was used throughout.
Qualitative data of the B2C form was independently
analysed and discussed by two researchers. Comments
specifying one of the pre-defined categories were used to
transform these into subcategories, and new upcoming
categories were added as they emerged from the data.
Qualitative analysis of in-depth interviews was per-
formed using a thematic framework approach (45). First,
interviews were transcribed verbatim and translated into
English. Initial familiarization with the data through
repeated review of the transcripts marked the first analy-
tical stage. The framework was developed on the basis
of objectives and themes emerging from the respondents’
answers. The developed categories were re-evaluated
and checked for reliability. As consequence, they could
either stand for themselves or were subsumed under
other categories, transforming them into subcategories.
They were also compared to the categories from the B2C
forms to control for credibility of the data. Themes and
subthemeswereillustrated bysupporting quotes (Table 3).
Interviews were coded in a database by two researchers
to ensure reliability and consistency of the coding criteria
(46). Discrepancies, when occurring, were openly dis-
cussed and resolved.
Ethical approval
InformedconsentfortheparticipationintheB2Cprogram
was obtained as part of the clinic registration. The Malawi
National Health Science Research Committee (NHSRC)
approves the collection and retrospective analysis of
routinedata.Priortothein-depthinterviews,writtenin-
formed consent was gained from all patients. Ethical
approval was obtained from the Malawi NHSRC and the
Ethical Research Board of the University Heidelberg/
Germany.
Results
Patients’ characteristics
Between January 2008 and December 2009, 14,121
patients aged 15 years and above received ART at the
Lighthouse. Within this period, 12.9% (n1,826) of these
patientswereidentifiedasLTFUpriortoascertainingtheir
actual ART status by the B2C programme (Fig. 1). The
B2C team identified 581 patientswith complete stop of all
prescribed antiretroviral drugs. A subset of these patients
(n347; 58.2% female, average age 35.1911.3 years)
returned to the clinic for continuation of therapy, here
definedaspatientswithTI. MeandurationofARTamong
patients with TI(s) was 15914.9 months (range 075
months),whichissignificantlybelowthemeanforpatients
with uninterrupted therapy between 2008 and 2009 (mean
25.8920.4; range 0125 months; pB0.0001; adjusted for
sexandage). Withinthegroup ofpatientswitha historyof
TI, 90.9% interrupted ART once, 7.8% twice and 1.25%
three times within the study period. The mean duration of
TI was 87987 days (range 22552) and was significantly
longer in males (mean 1039105 days) compared to
females (mean 75968 days) (p0.001, adjusted for age).
B2C form
In total, data from 147 patients with confirmed TI was
entered. This subset did not differ significantly from the
total number of patients with TI (n347) with regard to
their basic demographics (gender, age), duration of ART
prior to TI, and duration of TI. The majority of forms
were filled by the interviewer speaking with the patients
themselves (83.7%, n123/147), whereas if they could
not be contacted the interview was conducted with the
treatment supporter, the spouse or a close family member.
In over a third of cases more than one reason for TI per
patient was documented with the B2C form. The most
commonly stated reason for TI was travel (54.4%; n80/
147; Fig. 2). According to additional comments travel was
related to travel for work or family issues. The category
treatment fatigue/forgetfulness was selected by the inter-
viewer in 20.4% (n30/147) of cases, but was only chosen
six times as sole reason for TI and commonly associated
with the category travel. Next, patients stated transport
costs (19.0%, n28/147) as reason for TI. Less frequently
reported reasons were weakness/sickness (14%, n20/
147), religious reasons (7%, n10/147) and drug side
effects (4%, n4/147). Only one patient stated TI due to
use of traditional medicine. More than a quarter of the
patients (28%, n41/147) stated additional barriers to
continuous care, which exceeded the scope of the pre-
defined categories. The following reasons could be derived
from additional free-text comments: Health-care-provider-
related reasons were specified by 14% (n21/147) of res-
pondents. This category includes aspects such as perceived
rejection to receive ART re-fill (i.e. lost health passport,
site visits without appointment, admission to hospital),
or a disturbed relationship with the health care provider
through either perceived or enacted discriminatory beha-
viour. Perceived or enabled stigma by family, friends or the
employer (7%; n10/147) was also an obstacle to remain
in care. Some women (3%; n4/147) interrupted therapy
due to conditions related to their pregnancy or delivery.
Rare reasons were imprisonment (2%; n3/147) and
stopped ART by a clinician due to lactate acidosis with
consecutive LTFU (1%; n2/147).
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Fifteen females and eleven males were interviewed. The
median time of interview was 18 min. Demographics such
as age, sex, marital status, occupation and duration of
ART prior to TI were recorded (Table 1).
Factors known to support drug adherence and retention
in care
Basic knowledge about HIV/AIDS and ART. Generally
respondents had sufficient knowledge about HIV/AIDS,
the effect of antiretroviral drugs, the importance of ad-
herence, as well as possible consequences of TI (Table 2).
All respondents confirmed that the health care providers
gave information about ART at the time of therapy ini-
tiation. Almost all respondents were able to differentiate
between HIV and the development of AIDS. Similarly,
almost all respondents were aware of ARVs’ mode of
effect on HIV and the recovery of the immune system as
wellastheimportanceofregulardrugintakeasprescribed.
All respondents knew about ART as a lifelong therapy
(for illustrative quotes see Table 2).
Social support systems. All respondents reported that
they disclosed their HIV and treatment status to at least
one other person. The choice of whom to disclose to was
mainly based on trust and belief that the person would
respect and maintain confidentiality. All but one of the
17 married respondents disclosed to their spouses. Most
participants disclosed to relatives and close friends. A few
participants had disclosed to their employers, church
leaders and/or neighbours. The main reason for disclos-
ing was to ensure that in case of sickness a trusted person
could provide and seek care. In addition, patients dis-
closed to their spouse in order to encourage them to go
for HIV testing and counselling. Some participants
attended support groups. Most patients attending sup-
port groups were female. More than two thirds of the
respondents reported that their church supports HIV
testing and counselling as well as ART.
As a prerequisite for being initiated on ART in Malawi
and at the Lighthouse, patients are requested to name
a treatment supporter (‘guardian’) who is willing to
support him/her adhering to therapy. These guardians
are allowed to collect drugs instead of the patient, that is,
in case of illness. Some interviewees stated that disclosing
to only one person was challenging in case the trusted
person died or travelled. As a result, patients struggled to
identify another person who could step in as a guardian
(for illustrative quotes see Table 2).
Reason for TI
Based on the in-depth interview and information derived
from comments in the B2C form, the category travel was
differentiated into the subcategories work- and family-
related travel. Notably, men who travelled far distances
for a job obligation mainly stated travel for work.
Whereas women mostly stated family-related travel,f o r
example, they took care of a relative and had no means to
return home. Second, patients described health-care-
provider-related conditions like loss of health passport,
Fig. 2. Reasons for treatment interruption. Relative frequency of reasons for treatment interruption as stated by patients in the
B2C form n147; multiple reasons per patient possible. Additional categories exceeding the scope of the pre-deﬁned categories
were derived from the comment ﬁeld and are marked with a star: *.
B2C: Back-to-Care.
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criminatory behaviour of health care workers as the
explanation for delayed return to care. Another impor-
tant reason was financial limitations such as transport
costs. Furthermore, self-reported health conditions in-
cluding adverse effects, sickness/weakness, pregnancy and
treatment fatigue were also mentioned in in-depth inter-
views as drivers of TI (Table 3).
Discussion
We aimed at understanding reasons for TI in patients
on ART at the Lighthouse Clinic in Lilongwe, Malawi.
We evaluated a specific group of patients who temporally
interrupted ART, meaning these patients stopped ART
for a certain period of time but ultimately returned to
care to resume therapy. Evaluating their key character-
istics, factors supporting adherence and retention in care,
as well as individual circumstances leading to TI can
inform future adherence counselling: The provision of
problem-solving strategies targeting common barriers
to care is required to adequately support patients on a
lifelong therapy.
Differentiation between non-adherence and TI as
separate treatment outcomes (47), as done in this study,
is of growing importance. Kranzer et al. presented a
systematic review of studies from developed and devel-
oping countries specifically reporting TI as outcome and
evaluating frequency, reasons, risk factors, and conse-
quences of TI (31). However, only few of these studies
investigated reasons for TI for the setting of sub-Saharan
African countries especially for countries with ART
available free of charge.
Treatment guidelines at the Lighthouse, including
ART regimens and treatment monitoring, can be con-
sidered representative for Malawi (48). However, the study
site’s capacity regarding the number of patients treated,
quality management as well as monitoring and evaluation
effortsexceedstheaverageARTsiteinMalawi.Additional
features, such as the early active follow-up (B2C) pro-
gramme, aim to improve retention in care. Efforts to re-
tain patients appear to be successful since only 4.1%
of the overall treatment cohort stopped/interrupted
ART, which compares favourably to other settings (10).
Remarkably, more than half (59.7%) of these patients
returned to the clinic and resumed therapy. Furthermore,
most programmes do not trace patients LTFU and there-
fore cannot further distinguish their ART status as done
in this study setting to specifically target patients with
confirmed TI.
We evaluated key characteristics of patients with con-
firmed TI in comparison with patients who regularly
attended their scheduled clinical visits: The mean dura-
tion of ART was significantly shorter in patients inter-
rupting ART compared to patients who continuously
attended clinic visits; and duration of TI was significantly
longer in men when compared to women. This is consis-
tent with previous findings where stop of ART was
associated with male gender and time since ART initia-
tion  particularly during the first 6 months; and ART
resumption was more likely in women (30, 49). Retention
in care could be further improved by providing adher-
ence counselling specifically targeting patients in the first
months after ART initiation and services tailored for
male patients. Amongst other recommendations, Kranzer
at al. proposed late clinic hours providing care after
working hours, special support groups for men and
Table 1. Respondents’ characteristics: In-depth interview
(n26)
Female
(n15)
Male
(n11)
Total
(n26)
Age
Median 26 32 30
1519 3 0 3
2029 7 3 10
3039 3 5 8
4050 2 3 5
Marital status
Single 1 2 3
Married 9 8 17
Divorced/
separated
31 4
Widow 2 0 2
Occupation
Small scale
business
64 1 0
Housewife 2 0 2
House servant/
cook
30 3
Teacher 2 0 2
Student 1 0 1
(Truck) -driver 0 2 2
Gardener/farmer 1 2 3
Prisoner 0 1 1
Mechanic 0 1 1
Minibus caller 0 1 1
Duration on ART (months)
a
Only starter pack
b 30 3
266 6 1 2
712 1 2 3
1324 1 2 3
2536 2 1 3
 36 2 0 2
ART: Antiretroviral therapy.
aDuration on ART prior to interruption period in months.
bPatients initiated on ARTreceive a starter pack (14 day supply of
stavudine and lamivudine).
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of male patients (49).
In-depth interviews revealed a sufficient knowledge
about HIV/AIDS, the effect of antiretroviral drugs and
possible consequences of TI in most of the interviewed
patients. This reflects the emphasis the Lighthouse Clinic
places on treatment readiness assessments, adherence
counselling and regular patient education sessions. All
patients disclosed their HIV status to at least one person,
most frequently their spouse. The idea of disclosure is
to reveal one’s HIV status to a trusted person who can
maintain confidentiality and offers support if needed.
Patients who have not disclosed their HIV status to their
partners are more likely to miss doses than other patients
(5052). In our study, the motivation behind disclosure
appeared to be driven by the need for assigning or hav-
ing a treatment supporter. Treatment supporters have the
task to remind the patient of scheduled dosing times and
clinic appointments (50). Having a treatment supporter
is part of the ARTreadiness assessment in Malawi. When
a treatment supporter travelled or died, some patients
struggled to identify another person to step in to collect
drugs on their behalf. Consequently, the positive idea
of a treatment supporter might turn into an obstacle,
because patients felt they were no longer eligible for ART
continuation. Rachlis et al. made a similar observation
in another patient cohort in Malawi where lack of a
treatment supporter was incorrectly perceived as inelig-
ibility for ART as part of hospital policies (53).
Considering that most interviewees showed sufficient
knowledge about HIV/AIDS and ART and had treatment
supporters at their side, the study explored what other rea-
sons caused them to interrupt treatment. Previous research
from Malawi identified high transport costs, perceived
stigma, dissatisfaction with care, improved health, poor un-
derstanding of the disease and treatment as well as drug side
Table 2. Factors supporting with drug adherence and retention in care in patients with documented treatment interruption
(in-depth interviews; n26)
Basic knowledge about HIV/AIDS and ART Illustrative quotes
The patient was able to ...
...differentiate between HIV and AIDS HIV is a virus that causes AIDS, while AIDS is the accumulation of different diseases
caused when body immunity is low. (Female, 29 years, 37 months on ART)
...describe the effect of ARVs It is a type of medication that boosts one’s immune system and it is taken in every day of
one’s life, when one is HIV positive. Again ARVs help to prevent opportunistic infections.
(Male, 33 years, 28 months on ART)
...understand that ART is a lifelong therapy Because the virus will not be healed but will remain in the body the rest of life. It does not
mean that when we take the drugs, the HIV/AIDS will go, no. They are not like cough
treatment where we get healed, so we need to take them the rest of our life. (Female,
17 years, on starter pack)
...describe the possible consequences
of an interruption of ART
The importance is that when you adhere to treatment the virus cannot resist drugs and
that we will have healthy life. (Female, 28 years, 22 months on ART)
Social support systems Illustrative quotes
Disclosure to ...
...relatives. Disclosure to relatives: I told them to know so that I may get proper care and help when
I am sick, and also to know where to seek care, better a government facility than a private
clinic. (Female, 26 year)
...close friends. Disclosure to spouse: So that he may as well go for HTC [HIV testing and counselling].
(Female, 33 years)
...employer, church leader and/or neighbour. Disclosure to employer: So that he should not be surprised whenever I make an excuse to
be absent from work to go to the hospital as it has happened today. (Male, 32 years)
Support group We encourage each other and care for people who are very ill, that can’t work on their
own. (Female, 29 years, married)
Support through church/religion They normally talk of how best an HIV patient can live as well as encouraging people to
adhere to treatment. (Female, 39 years)
Treatment supporter/guardian* I was advised to come for another counselling session with a guardian at a given date but
a problem was which guardian [treatment supporter] I could bring since my wife is away,
my brother is a busy person. (Male, 33 years)
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral therapy; HIV: human immunodeficiency virus.
*All respondents had a documented treatment supporter; however, some patients stated challenges as shown in the illustrative quote.
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defined categories of the B2C form, the most commonly
s t a t e dr e a s o nf o rT Iw a stravel followed by treatment fatigue/
forgetfulness and transport costs. The analysis of free-text
comments revealed additional barriers to continuous care
exceeding the scope of the pre-defined categories such as
health-care-provider-related reasons for TI. The selection
of multiple pre-defined categories as well as the variety of
additional reasons for TI derived from free-text com-
ments stressed the need for in-depth analysis. We therefore
conducted a qualitative analysis of the free-text comments
and conducted a number of purposively sampled in-depth
interviews togain a deeperunderstanding of pre-defined and
newly derived reasons for TI.
The pre-defined category travel was further differen-
tiated into travel related to work obligations or family
issues, such as taking care of a relative or attending a
funeral. These causes reflect both economic and strong
personal factors, which apparently outweighed patients’
knowledge and awareness of the possible consequences
of TI and were given priority over keeping an appoint-
ment. Despite these personal circumstances most of
these patients were generally willing to continue ART.
The provision of additional drug supplies on short notice
as well as the transient transfer to other ART facilities
could be part of a more flexible ART programme res-
ponding to the patients’ individual circumstances.
The category treatment fatigue included forgetfulness
or feelings of being overwhelmed by the challenge to adhere
toART.Newapproachestrytousemobilephonesandtext
messages to remind patients of their next appointment,
a technology which can also be used for real-time measure
of adherence among patients receiving ART (57). Studies
using mobile devices in Ghana and Kenya demonstrated
Table 3. Reasons for treatment interruption (in-depth interviews; n26)
Categories Definition Illustrative quotes
Travel (n16)
Family related Patient was travelling far in order to support family
members. The distance to the clinic caused the
treatment interruption.
I went to a funeral in Balaka, but failed to come back on
time because I didn’t have transport money. (Female,
22 years)
Work related Patient was travelling far because of any kind of work,
a job opportunity or assignment. The distance to the
clinic caused the treatment interruption.
Since I am a labourer, I went to Dzalanyama to collect
firewood, unfortunately had a car breakdown, slept
there and did not carry my medicine. (Male, 44 years)
Financial barriers (n7)
Transport cost The patient could not afford the transport to the health
centre, because of the distance and/or the lack of
money.
Sometimes I even lack transport to come here
from Chinsapo to collect my medication. (Female,
23 years)
Own health related (n 6)
Adverse drug effects The patient suffered from strong adverse effects of
ART. He/she stopped treatment in order to improve
his/her well-being.
I was having rashes, dizziness, stomach-ache and
swollen legs (Female, 26 years)
Weakness/Sickness The patient suffered from any symptoms not
necessarily related to ART. He/she stopped because
of illness.
I stopped because I was sick; had terrible headache
and coughing (Female, 24 years)
Pregnancy/delivery The patient was pregnant and or delivered a baby
when she was supposed to collect drugs from LH/
MPC. Her special condition detained her from
collecting the drugs.
That time I had just delivered this baby so had no
strength to walk to here. (Female, 33 years)
Health provider related (n8)
Perceived rejection to
receive ART re-fill
The patient felt/was told not to fulfil the requirements
to collect ARTat the centre. He/she therefore avoided
going to the health centre.
I lost my health passport book through robbery. [...]
I thought that I could not be helped without this book.
(Female, 42 years)
Disturbed relationship
to health care provider
The patient experienced/perceived difficulties
collecting new drugs from the health centre. He/she
therefore avoided going to health centre.
I was afraid I could be shouted at by the Doctor
(Female, 22 years)
General adherence (n1)
Treatment fatigue The patient was overwhelmed by the challenge
to adhere to ART. He/she gave up and stopped
therapy.
Laziness, and sometimes I take the medication without
food, which raises fears in me. (Female,
23 years)
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ence (58, 59). However, reasons for TI as found in this
study go beyond general forgetfulness and our data sug-
gests that ‘simple’ technical reminders might be useful
but not necessarily sufficient in all cases. In this study,
treatment fatigue was only stated six times as the sole
reason and commonly associated with the category travel.
This phenomenon might therefore be a result of an
interviewerbias,astheB2Cteamsummarizedthepatient’s
statements under the pre-defined categories. This is also
supported by the findings of the free-text comments and
in-depth interviews revealing more specific reasons for TI.
AnothermainreasonforTIwasreportedtobetransport
costs, which hindered patients from coming to the clinic.
Transport costs constitute a barrier to care, as they often
compete with other costly demands such as food, housing
or school fees, thereby compromising access to care (34).
This in turn may result in the interruption of treatment.
According to Boyer et al. (47) financial factors appear
as main drivers of TI (47). Meanwhile ART in Malawi
isprovidedat 655sitesandfreeofcharge,whichis thought
toreducetransportcostsandincreaseaccessibilitytoART
(60). However, this advantage may be partially counter-
acted by increased travel cost following inflation (61).
Further, the category of health-care-provider-related
reasons, such asperceived ineligibilityforART,f o re x a m p l e ,
the lack of a treatment supporter or a health passport
or a disturbed providerpatient relationship was reported
in free-text comments of the B2C form. This finding
underlines the importance of the interaction between the
individual patient and the health care provider. Misleading
and rigid hospitalpolicies shouldbeavoided and the health
care provider needs to be perceived as a partner in care
reducing logistical barriers. The acknowledgement of the
patient’s perception to be stigmatized (53) and the preven-
tion of discriminatory behaviour of the health personnel
is also crucial for the health care provider  patient
relationship.
However, it should be noted that treatment fatigue,
transport costs and health-care-provider-related reasons
combined were less frequently reported than travel alone,
underlining its relevance and stressing the need to address
the issue.
Our findings may therefore result in practical impli-
cations for patient management and adherence support
strategies. Rather than ‘simple’ technical reminders such
astextmessages,moreflexibilityinthedrugre-fillschedule
and counselling addressing the identified reasons for TI
providing problem-solving strategies are needed, which
have already been partially introduced at the Lighthouse
as a result of this study.
Limitations
Our study had several limitations. First, only patients
with TI resuming therapy were included. Patients not
returning to care could not be interviewed and may have
other reasons for stopping ART completely. It needs to
be emphasized that at the Lighthouse the majority of
patients resume therapy after a period of interruption
and we were particularly interested in their reason for
TI. Our findings confirmed that these patients inter-
rupted ART for temporary obstacles and most of them
never intended to ultimately stop ART.
Second, ART counsellors filled B2C forms and the
evaluation of additional comments was done retrospec-
tively. Also, it cannot be fully determined to what degree
respondents replied truthfully or whether answers were
subject to desirability bias. Finally, only subsets of patients
with TI were included for the analysis of B2C forms and
only few patients were further selected for in-depth inter-
views. Although basic characteristics showed no signifi-
cant differences between patients with TI and the subset of
enrolledpatientsfortheanalysisofB2Cforms,andin-depth
interviews were continued until a point of saturation was
reached, this approach might be subject to a selection bias.
Conclusion
Improved retention in care and adherence to therapy
must be considered as two of the main pillars of national
ART programme success. Both retention and adherence
have the potential to effectively reduce subsequent treat-
ment failure. Addressing the challenges of supporting pa-
tients on lifelong therapy, strategies must be developed
that preventorreduce discontinuationof ART. Aprofound
understandingofreasonsforTIisthebasisforinterventions
such as needs-adjusted counselling, providing problem-
solving strategies specifically targeting common adherence
challenges like travel or health-system-related barriers.
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